80% of COVID-19 patients in study were vitamin D-deficient

pharmafile | October 28, 2020 | News story | Research and Development  

New research has found that over 80% of COVID-19 patients in a recent study had a vitamin D deficiency. 

The new study was published in the Journal of Clinical Endocrinology & Metabolism and looked at 216 COVID-19 patients in a hospital in Spain. It found that 82.2% were deficient in vitamin D, and it also found that these people had longer hospital stays from the virus. 

The study concluded: “We have found that serum 25OHD levels are significantly lower in hospitalised COVID-19 patients compared to population-based controls of similar age and sex and that these differences remain significant even once adjusting for the main confounding factors. These levels were especially lower in the group of men with COVID19. Despite the high frequency of vitamin D deficiency in patients hospitalised for COVID-19, we did not find an association between circulating levels of 25OHD and the severity of SARS-CoV-2 infection.”

The link between vitamin D deficiency and COVID-19 has been explored since the pandemic began. Some of the comorbidities that have caused coronavirus fatalities, like diabetes and obesity, are associated with low vitamin D levels. This study is also reflective of wider research into how vitamin D can help people recover from the virus.

Jose L. Hernandez, the study co-author from the University of Cantabria in Santander, said: “One approach is to identify and treat vitamin D deficiency, especially in high-risk individuals such as the elderly, patients with comorbidities, and nursing home residents, who are the main target population for the COVID-19.

“Vitamin D treatment should be recommended in COVID-19 patients with low levels of vitamin D circulating in the blood since this approach might have beneficial effects in both the musculoskeletal and the immune system.”

Conor Kavanagh

Related Content

No items found

Latest content